Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Frontiers in Medicine

article

Michele Balma¹  Virginia Liberini¹  Manuela Racca³  Riccardo Laudicella⁴  Matteo Bauckneht⁷  Ambra Buschiazzo¹  Daniele Giovanni Nicolotti¹  Simona Peano¹  Andrea Bianchi¹  Giovanni Albano⁶  Natale Quartuccio⁹  Ronan Abgral^1,10  Silvia Daniela Morbelli⁷  Calogero D'Alessandria^1,11  Enzo Terreno^1,12  Martin William Huellner⁵  Alberto Papaleo¹  Désirée Deandreis² 

[1] Nuclear Medicine Department, S. Croce e Carle Hospital;Division of Nuclear Medicine, Department of Medical Science, University of Turin;Nuclear Medicine Unit, Candiolo Cancer Institute;Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina;Department of Nuclear Medicine, University Hospital Zurich, University of Zurich;Nuclear Medicine Unit, Fondazione Istituto G. Giglio;IRCCS Ospedale Policlinico San Martino;Department of Health Science ,(DISSAL), University of Genoa;Nuclear Medicine Unit, A.R.N.A.S. Civico di Cristina and Benfratelli Hospitals;Department of Nuclear Medicine, University Hospital of Brest;Department of Nuclear Medicine;Department of Molecular Biotechnology and Health Sciences, Molecular & Preclinical Imaging Centers, University of Turin

关键词: PET;    breast cancer;    radiotracers;    molecular imaging;    FES;    FLT;    FAPI;    PSMA;   

DOI  :  10.3389/fmed.2022.881551

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.

【 授权许可】

CC BY